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CObjective: A head-to-head comparator study has shown that the
clinical efficacy of ustekinumab is superior to that of etanercept over
a 12-week period in patients with psoriasis. Economic models are
often hindered by the lack of trials directly comparing outcomes
between relevant alternative therapies. The aim of this analysis was
to evaluate the cost-effectiveness of ustekinumab versus etanercept
among adults with moderate-to-severe plaque psoriasis based on a
Phase 3 head-to-head trial. Methods: The Markov model incorpo-
rates trial data from the Active Comparator (CNTO 1275/Enbrel) Pso-
riasis Trial study (ustekinumab 45 mg at Weeks 0 and 4; etanercept
50 mg biweekly) to follow patient response to initial treatment using
the modeling approach developed by the Centre for Reviews and
Dissemination, University of York, and often cited by others con-
ducting economic analyses of psoriasis. Beyond the initial trial pe- O
tion,
al So
oi:10.1016/j.jval.2011.01.006iod, the Canadian model extrapolates results up to 10 years.
esults: Over the 10-year time horizon of the model, the mean an-
ual costs were $16,807 for ustekinumab (45 mg) and $19,525 for
tanercept (50 mg). The incremental difference in costs and utilities
emained in favour of ustekinumab across a range of sensitivity
nalyses. Conclusions: This model highlights the advantage of hav-
ng head-to-head comparative trial data relevant to the at-risk pop-
lation. Our model shows that ustekinumab is more cost-effective
han etanercept for patients with moderate-to-severe plaque psori-
sis.
eywords: Canada, cost utility analysis, Markov model, psoriasis.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In a head-to-head comparator study, the clinical efficacy of usteki-
numabwas superior to that of etanercept over a 12-week period in
patients with psoriasis [1]. Earlier PHOENIX studies have demon-
strated the effectiveness of ustekinumab given every 8 to 12weeks
in the treatment of moderate-to-severe psoriasis, and this benefit
is maintained for at least a year in most patients [2,3]. Addition-
ally, the benefits of ustekinumab extended beyond those indicated
by clinical measures as evaluated by health-related quality of life
and other patient-reported outcomes [4,5].
Clinical trials designed to demonstrate the efficacy and safety of
an intervention against placebo are the typical data sources formod-
els, but these data do not represent the real-world environment
where new interventions are typically compared to the standard of
care. Therefore, theavailability of data fromthePhase3,multicenter,
randomized Active Comparator (CNTO 1275/Enbrel) Psoriasis Trial
(ACCEPT) [1] provides auseful basis tomodel the long termeconomic
impact usinghead-to-head trial datawith theobjective of comparing
the costs and utilities of ustekinumab (Stelara, Centocor, Horsham,
PA) versus etanercept (Enbrel, Wyeth, Pfizer, New York, NY) in pa-
tientswhohavehadan inadequate response to,were intolerant to, or
* Address correspondence to: Feng Pan, United BioSource Corpora
E-mail: feng.pan@unitedbiosource.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.havecontraindications toat least oneconventional systemic therapy
or phototherapy (e.g., ultraviolet B rays). Because etanercept is the
most commonly used and recommended agent in Canada for this
moderate-to-severe psoriasis population, itwas selected as the com-
parator for theACCEPT trial. About 48%of the study populationwere
from Canada, so the ACCEPT study is well suited for incorporation
into a pharmacoeconomic analysis intended for Canadian reim-
bursement authorities [6].
Methods
The model used in this cost utility analysis incorporates the widely
acceptedpsoriasis-relevantassumptions fromthehealth technology
assessment (HTA) report undertaken by the Centre for Reviews and
Dissemination, University of York, UK, for the UK National Health
Service. The York model compared etanercept and efalizumab and
has been widely cited by others developing economic analyses of
psoriasis drugs [7]. Following their approach, the currentmodel uses
the Psoriasis Area and Severity Index (PASI) response over the dura-
tion of therapy and extrapolates it into the future using follow-up
maintenance therapy, and uses a constant withdrawal rate, regard-
7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
653V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 – 6 5 6less of the therapy, to manage treatment discontinuations because
no alternative data exist.
Our model differs from the York model by focusing on a single
comparison between ustekinumab and etanercept using direct data
from a head-to-head trial rather than indirect data from a mixed
treatment comparisonofmultiple treatments. Themodel focuses on
patients in Canada who are refractory to at least one conventional
systemic therapy or phototherapy. Data used to map utility from
PASI response were estimated based on ustekinumab trials [2,3]. In
addition, Canadian treatment patterns and costs were used.
Model description
A Markov model was designed in Microsoft Excel (Microsoft 2003,
Microsoft Corp, Redmond, WA) to compare ustekinumab with et-
anercept in the management of moderate-to-severe refractory
plaque psoriasis patients from the perspective of the Ontario Min-
istry of Health. The model was made up of two phases. The first
phase, the initial trial period, incorporated the data from the head-
to-head ACCEPT study, where ustekinumab and etanercept were
compared in severe psoriasis patients considered high-need (i.e.,
refractory to conventional systemic therapy or phototherapy). The
second phase, the maintenance period, extrapolated the ACCEPT
data to 10 years, an appropriate time horizon accepted by health
technology appraisers for UK National Institute for Health and
Clinical Excellence and the Canadian Agency for Drugs and Tech-
nologies in Health.
All modelled patients started on either ustekinumab or et-
anercept during the initial trial period and incurred a fixed cost
related to the treatment regimens described in ACCEPT. The
probability of treatment success during this initial trial period
was defined as achieving a PASI 75 response, reflecting a greater
than or equal to 75% improvement from baseline as measured
by PASI, the primary clinical endpoint. Only those with PASI
response greater than or equal to 75 continued into the main-
tenance period; nonresponders (PASI  75) discontinued ther-
apy and received best supportive care. The maintenance period
had two health states: continuing response and discontinua-
tion, an absorbing health state that included those patients who
had stopped treatment due to various reasons, including treat-
ment failure and adverse events. (see Figure 1). The model as-
sumes that those who continued treatment in maintenance pe-
riod retained a PASI response of 75 until treatment
discontinuation. This assumption is well supported by the long-
Fig. 1 – Psoriterm efficacy data from PHOENIX 1 and PHOENIX 2 trials [2,3].The status of patients was determined in each 3-month cycle
(t1, t2, tn) at which time they either remained in response or
moved to the treatment failure state.
Before determining final results, the structure and program-
ming of the completed Microsoft Excel model was validated by a
modeling expert not involved in this study,which entails reviewof
modeling approach, assumptions, as well as the implementation
of model calculations and analyses. In addition, a variety of stress
tests were performed to ensure that themodel results were reflec-
tive of the inputs entered.
Model parameter values
ACCEPT included 903 adult patients with chronic plaque psoriasis
(etanercept 347, ustekinumab 45mg 209, ustekinumab 90mg
347) who had failed to respond to, had become intolerant of, or had
contraindications to conventional systemic therapy (e.g.,methotrex-
ate and cyclosporine) or phototherapy [1]. Patientswere randomized
to receive subcutaneously administered ustekinumab or etanercept.
Patients administeredustekinumab received45mgor 90mgdoses at
Weeks 0 and 4. Patients in the etanercept group received twice-
weeklydosesof50mgfor12weeks.Basedontheprimaryendpointof
PASI 75 at Week 12, a significantly higher proportion of patients re-
ceiving ustekinumab 45 mg were responders at Week 12. For the
purpose of the present cost-utility analysis, themodel used only the
data from the dose principally recommended in the Canadian prod-
uct monograph, the 45 mg dose.
Response and discontinuation rates
Trial response rates (Table 1) were utilised to determine the
proportion of patients achieving PASI 75 at 12 weeks and thus
eligible to enter the maintenance period of the model. During
this second period, 45 mg ustekinumab was administered every
12 weeks and 50 mg etanercept was administered weekly re-
flecting maintenance therapy. Patients who respond to therapy
atWeek 12 were assumed to remain on continuous therapy with
the same PASI 75 response rate and utility for the remaining
time horizon unless they discontinued. The safety of usteki-
numab and etanercept, including the rates and types of adverse
events, were generally similar during the 12-week comparator
portion of the trial and there was no evidence to suggest differen-
tial discontinuation rates over the longer term maintenance pe-
riod. Thus, an annual 20% discontinuation rate was assumed re-
model flow.asisgardless of therapy. This assumption was adopted from HTA
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654 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 – 6 5 6reports [7,8] on psoriasis and verified by Delphi panel of Canadian
clinical experts.
Thereweremore injection site reactions among etanercept pa-
tients (22.2% vs. 2.9%) than in the ustekinumab group [1]. In an
effort to keep our analysis conservative, the rate of injection site
reactions was not included in the model either as a cost conse-
quence or as a decrease in patient utility. Mortality was not in-
cluded in the 10-year model as there were no data indicating any
difference between the therapies. It was assumed any mortality
during the trial would have been due to nonpsoriasis causes and
would be equivalent across therapies.
Utility values
Incremental improvement in utility values were applied to pa-
tients based upon their change from baseline PASI score achieved
in ACCEPT [1]. Given PASI data do not provide utility values, the
Dermatology Life Quality Index (DLQI)was transformed into utility
values using an ordinary least squares linear regression calcula-
tion as presented in the HTA assessment [7]. The regression cal-
culation used data from the Health Outcomes Data Repository
where both EuroQol-5D (EQ-5D) andDLQI datawere collected from
patients. Since ACCEPT did not collect DLQI data, the scores were
obtained from the two pivotal Phase 3 randomized, double blind,
placebo-controlled trials of ustekinumab—PHOENIX 1 and PHOENIX
2 [2,3]—to provide patient-level data for the regression analysis.
The two PHOENIX trials included patients with moderate-to-se-
vere psoriasis and used the same dosing schedule as in ACCEPT. It
was assumed that the utility changes associated with PASI re-
sponse in the PHOENIX trials would be similar to those in ACCEPT.
Both trials had a large number of Canadian participants, were in
similar patient populations, included patients with similar sever-
ity and duration of disease, and had comparable demographic fac-
tors at baseline. Themean change in theDLQI score between base-
line and Week 12, for the PASI response categories ( 50, 50–75,
Table 1 – Clinical response of 45 mg ustekinumab and
50 mg etanercept at 12 weeks (ACCEPT trial).
Etanercept
50 mg*
Ustekinumab
45 mg*
Patients randomized (Week 0) 347 209
PASI 50 responders Week 12 286 (82.4%) 181 (86.6%)
PASI 75 responders Week 12 197 (56.8%) 141 (67.5%)†
PASI 90 responders week 12 80 (23.1%) 76 (36.4%)‡
PASI, Psoriasis Area and Severity Index.
* ACCEPT (Griffiths et al. [1]).
† P  0.0112.
‡ P  0.001.
Table 3 – Psoriasis model costs*.
Drug Drug price
Costs for initial trial period (12 wks)
Etanercept 50 mg (biweekly) $9,404.88
Ustekinumab 45 mg (0,4 wks) $8,400.00
Costs for maintenance treatment period
Etanercept 50 mg weekly $20,447.22
Ustekinumab 45 mg q 12 wks $18,262.50
Palliative care 
* All costs are in the Canadian dollar.
† Ontario Ministry of Health Schedule of Benefits for Laboratory serv
‡ Ontario Ministry of Health Schedule of Benefits and Fees [10].75–90, and 90)were calculated using pooled patient data (regard-
ess of treatment arm) and mapped to the change in EQ-5D using
he published regression [8]. Thus, utility gains (Table 2) associ-
ted with each PASI response level were combined with the pro-
ortion of patients responding at that PASI level during the initial
rial period based on the equations provided byWoolacott et al. [8].
Once patients became eligible for maintenance therapy, the PASI
75 and PASI 90 weighted utility increments remained unless the
patient discontinued therapy.
Resource use and costs
Resource use was estimated by a panel of physicians experienced
in managing severe plaque psoriasis patients in Canada, which
was subsequently validated through a Canadian burden of illness
study [9]. The monitoring tests and physician visits for etanercept
and ustekinumab during the initial trial period of the model were
the same (two of each full blood count, liver functioning, and urea
and electrolyte lab tests and three physician visits) and were also
the same in the post-trial maintenance period (annually four phy-
sician visits and two of each of the same tests used during the
initial period). Dermatology visit costs are $20.60 each [10] and lab
tests are $8.27 for full blood count, $11.89 for liver functioning and
$7.77 for urea and electrolyte test [11]. Resource use for best sup-
portive care was estimated as six annual physician visits and no
laboratory monitoring tests. It was assumed that there would not
be any hospital admissions for any of these patients.
Drug costswere calculated for the initial trial andmaintenance
period (applied in threemonthly increments). The 45mgunit price
of ustekinumab was $4200 and the 50 mg unit price for an etaner-
cept prefilled syringewas $381.97 (manufacturer price list). Table 3
lists the costs for both periods of the model by therapy. Costs are
Table 2 – Utility value fains according to Psoriasis Area
and Severity Index (PASI) level.
PASI response category Utility gains for all patients
PHOENIX
calculation*
TA 146
calculation†
50 0.0400 0.063
5 0 and 75 0.1700 0.1780
75 and 90 0.2200 0.1780
90 0.2500 0.3080
* Calculated from PHOENIX 1 and 2 using regression presented in
Woolacott et al. [8].
† Basedon trial data fromadalimumabsubmission toUKNational Insti-
tute for Clinical Excellence (TA 146,manufacturers submission).
Monitoring† Outpatient visits‡ Total
$55.86 $61.20 $9,521.94
$55.86 $61.20 $8,517.06
$55.86 $81.60 $20,584.68
$55.86 $81.60 $18,399.96
 $123.60 $123.60
11].ices [
cates
655V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 – 6 5 6calculated as the increment above any standard therapy applied
equally across the comparative therapies.
Sensitivity analysis
One-way sensitivity analyses were conducted on parameter val-
ues to examine their affect on the incremental cost-effectiveness
ratio, including discount rate (5.0% base case for costs and out-
comes), time horizon, discontinuation rate, and utility values for
PASI scores as reported in the HTA report of adalimumab for pso-
riasis [7]. Probabilistic sensitivity analysis was also conducted by
varying model parameters randomly across their potential distri-
butions over 10,000 iterations. The analysis here assumes beta
distribution for PASI responses; and normal distribution for the
mapping coefficients from PASI response to DLQI and from DLQI
to EQ-5D.
Results
Over the 10-year timehorizon of themodel, themean annual costs
were $16,807 for ustekinumab (45 mg) and $19,525 for etanercept
(50mg). The average duration of therapywas 2.77 years for usteki-
numab and 2.35 years for etanercept, applying the 20% annual
discontinuation rate to both therapies. The incremental cost is
$2718 less for ustekinumab with a 0.0046 incremental increase in
mean annual qulity adjusted life years based on the higher pro-
portion of patients achieving PASI 75 and PASI 90 scores. Thus,
ustekinumab dominated etanercept because of lower costs and
higher utility values (Table 4).
Sensitivity analyses were conducted to estimate the influence
of assumed variables (Table 4). Changing the rate of discontinua-
tion between 0% and 90% had no affect on the model outcomes
because it was applied across both treatments equally. The incre-
mental difference in costs andutilities remained in favor of usteki-
numab across the entire range of discontinuation. Reducing the
model’s time horizon to 2 or 5 years did not change the ultimate
outcome of ustekinumab dominating etanercept. Similarly,
changing the discount rates did not change the outcome. Using
the utility values derived directly from EQ-5D scores as reported in
the HTA report of adalimumab for psoriasis [7] increased the util-
ity values of both therapies and increased the incremental differ-
ence originally found between the two from –0.0046 to –0.0153.
The utility gain with ustekinumab versus etanercept was greater
with this parameter change and thus ustekinumab remained
dominant.
The probabilistic analysis indicated that ustekinumab is
likely to remain dominant over etanercept. A scatter plot (Figure
2) indicates that utility values are usually better for patients on
ustekinumab and costs range between $2200 and $3500 lower
Table 4 – Cost-effectiveness of ustekinumab versus etaner
Parameter Parameter value - range of var
Base case Discontinuation rate: 20%
Time horizon: 10 y
Discount rates: 5% for both cost and Q
Utility mapping: PHOENIX calculation
Discontinuation rate 0%–90%
Time horizon 2 y, 5 y
Discount rate 0%, 3%
Utility mapping Use value reported in adalimumab NI
QALY, Quality-adjusted life years; NICE, National Institute for Clinica
* All costs are in the Canadian dollar.
† See Table 2 for utility gain according to PASI response level; ( ) indithan etanercept. The mean and median costs are $2725 and$2723 less, respectively with a 95% confidence interval of
–$3,068 to –$2,422. The annual incremental utility is 0.0046
(mean) and 0.0040 (median) with a 95% confidence interval of
0.0001 to 0.0112. Thus, over a variety of assumptions as demon-
strated by the sensitivity analyses, ustekinumab has a lower
cost and greater utility gains than etanercept inmanaging severe
plaque psoriasis patients.
Discussion
This cost utility analysis indicated that ustekinumab (45 mg
every 12 weeks) has lower cost with better outcomes over a
10-year period compared with etanercept (50 mg twice weekly
for 12 weeks followed by weekly doses). Themodels showed that
ustekinumab consistently dominate etanercept. The finding was
stable under a variety of sensitivity analyses. Despite the conser-
vative assumptions made in this study, the costs associated with
the administration of etanercept are consistently higher than
costs for ustekinumab.
This model has two distinct advantages from previous health
economic models that often rely on evidence synthesis to under-
take indirect comparisons. First, it is based upon ACCEPT, the
head-to-head comparative trial of ustekinumab and etanercept
[1], a departure from indirect computation of cost utility from dif-
ferent placebo-controlled trials. Second, the model derives its
principal assumptions from a widely accepted psoriasis model—
the York model created for a UK National Institute for Health and
Clinical Excellence technology assessment [8]. In our study, the
assumptions of patients’ discontinuation rate, model duration,
and application of utility values to PASI scores were validated in a
review by Canadian dermatologists. Using assumptions consis-
tently acrossmodels and analyzing therapies for the same disease
base case and one-sensitivity analyses*.
n Mean annual
incremental costs
Mean annual
incremental QALY
($2,718) 0.0046
($2,061)–($7,854) 0.0037–0.011
($4,047), ($3,083) 0.0062, 0.0050
($3,029), ($2,831) 0.0051, 0.0048
port† ($2,718) 0.0153
ellence.
negative number.
Fig. 2 – Scatter plot of probabalistic analysis of incremental
difference in costs and quality-adjusted life years (QALYs)cept,
iatio
ALY
*
CE re
l Excbetween ustekinumab and etanercept.
t
s
f
t
b
P
n
b
t
n
m
t
t
w
n
s
t
s
o
s
t
b
u
s
a
t
v
a
u
7
w
R
t
h
o
e
a
656 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 – 6 5 6helps to narrow differences and potentially makes the findings
more useful for decision makers.
Because the ACCEPT trial included approximately 48% patients
from Canada, its outcomes are expected to be representative of
refractory moderate-to-severe psoriasis patients in the general
Canadian population. Although there are a number of therapies
used to treatmoderate-to-severe psoriasis in Canada, biologics are
recommended and used when patients have failed, are intolerant
or have contraindicated to systemic therapies or phototherapy
(e.g., ultraviolet B rays). The ACCEPT trial focused on refractory
patients who had experienced conventional therapies, and com-
pared ustekinumab to etanercept—the most used and recom-
mended biologic in Canada. Therefore, from the perspective of
Canadian reimbursement authorities, etanercept was the most
appropriate comparator for the cost-effective analysis. Data from
he 12-week head-to-head trial were used in the model with the as-
umption that the responsewouldbemaintainedover the long-term
or both ustekinumab and etanercept if patients remained on the
reatment. In the case of ustekinumab, this assumption is supported
y analyses of 1 and 1.5 years duration of data from PHOENIX 1 and
HOENIX 2 [2,3] demonstrating sustained efficacy with mainte-
ance dosing. Intermittent dosing for psoriasis management has
een considered in some jurisdictions, but the Canadian regula-
ory authority has recommended maintenance dosing for usteki-
umab (45mg administered every 12weeks) and for etanercept (50
g every week). Moreover, two published randomized controlled
rials show that continuous use of etanercept is clinically superior
o intermittent use of etanercept [12,13]. Thus, continuous dosing
as used in our economic analysis.
Although the results and sensitivity analyses indicate robust-
ess of the conclusions, there are limitations that warrant discus-
ion. The ACCEPT trial did not collect resource use data nor were
here any Canadian databases to elicit information on the re-
ources utilized by psoriasis patients. This cost utility study relied
nly upon expert clinical opinion supported by a recent Canadian
urvey of ninety moderate to severe psoriasis patients reporting
heir resource use [9].
Second, the regression equation upon which the relationship
etween DLQI and EQ-5D utility values is based on was derived
sing data from a UK population and assumed a linear relation-
hip between the two scores. It is not known whether the values
re transferable or appropriate to the Canadian population. Also
he linearity between the DLQI and EQ-5D scores has not been
alidated. The utility values, however, are conservatively applied
cross both therapies resulting in a small difference in favour of
stekinumabdue to thehigherpercentageofpatients achievingPASI
5 response. Third, the rate of patient discontinuation in ACCEPT
as similar to thatused in thepreviouslydescribedHTAreports [7,8].
egardless, our cost utility analysis employed a 20% rate of discon-
inuation equally across both therapies.
This model highlights the great advantage of having head-to-
ead comparative trial data relevant to the at-risk population. Itffers an approach to adopt similar assumptions from other mod-
ls within the disease area, making it easier for health authorities
nd payers to interpret the findings.
Conclusions
The presentmodel indicates that ustekinumab ismore cost-effec-
tive than etanercept for patients with moderate-to-severe plaque
psoriasis.
Source of financial support: Provided by Janssen Inc.
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